Hepatitis B
Two guidelines: EASL 2025 (current European) and AASLD 2018 (US guidance). Both recommend entecavir, tenofovir (TDF or TAF) or PEG-IFNα as first-line treatment.
Where they differ
| EASL 2025 | AASLD 2018 | |
|---|---|---|
| Treat chronic hepatitis | HBV DNA ≥2,000 IU/mL + ALT >ULN and/or significant fibrosis | ALT ≥2 × ULN (or significant histology) + DNA >20,000 (HBeAg+) or >2,000 (HBeAg−) |
| ALT upper limit | Laboratory ULN | 35 U/L men, 25 U/L women |
| Cirrhosis | Treat any detectable DNA | Treat (compensated with DNA >2,000; decompensated any DNA) |
| Pregnancy | Tenofovir if DNA ≥200,000, start before the third trimester | Tenofovir in the third trimester if DNA >200,000 |
Clinical pearls
- HBsAg + anti-HBc before any immunosuppression; rituximab is the highest-risk drug.
- HBeAg-negative chronic hepatitis is commoner in Asia (precore/core-promoter mutants).
- Always test for HDV in HBsAg-positive patients.